XAGE1B long-peptide vaccine

The XAGE1B long-peptide vaccine is an investigational therapeutic cancer vaccine developed by the Leiden University Medical Center (LUMC) for the treatment of non-small cell lung cancer (NSCLC), specifically pulmonary adenocarcinoma. The vaccine consists of long synthetic peptides derived from the XAGE-1b cancer/testis antigen, which is highly expressed in approximately 50% of lung adenocarcinomas but absent in normal tissues. It is typically administered in combination with the TLR3 agonist adjuvant poly-ICLC to enhance the induction of tumor-specific T-cell immune responses. The vaccine is currently being evaluated in Phase I clinical trials to assess its safety and immunogenicity.

Other names

XAGE1B long peptide vaccineXAGE-1B long peptide vaccineXAGE 1B long peptide vaccine